Friday, December 23, 2011

Gladstone, Bristol-Myers Squibb strike Alzheimer's research deal

The Gladstone Institutes will work with drug giant Bristol-Myers Squibb Co. in a basic research partnership to identify and validate Alzheimer’s disease targets.
Exact financial terms of the deal were not disclosed, but Bristol-Myers Squibb (NYSE: BMY) will fund Gladstone efforts to find targets that affect dysfunction of Tau, a protein that may help regulate the activity of brain cells.

No comments:

Post a Comment